promedpharmallc.com

What It Is

ProMed Pharma is a U.S.-based contract development and manufacturing organization (CDMO), not a SaaS or enterprise software product. Its core focus is the development and production of long-acting injectables, implantable dosage forms, and drug-device combination products, with particular emphasis on polymer-based controlled-release drug delivery technologies. The company has nearly 20 years of operating history as ProMed Pharma, while its parent organization has more than 30 years of experience in molding small, complex silicone and plastic implantable medical device components.

Core Capabilities

Its service chain covers early-stage formulation and feasibility studies, technology transfer, process optimization and scale-up, cGMP manufacturing, device assembly, packaging, sterilization management, as well as analytical and stability testing. The materials indicate that ProMed is skilled in molding, extrusion, and microencapsulation, and uses polymer excipients such as silicones, thermoplastics, and biodegradables. For highly potent APIs, the company states that it has experience handling OEB Class 4 or higher compounds and is equipped with custom isolators to control exposure risks.

Pricing and Delivery

The website does not publish packages, pricing, or payment methods, offering only a Request a Quote option, indicating a typical project-based quotation model. For early-stage projects, ProMed mentions that it can rapidly validate concepts within 4–8 weeks, but specific costs, capacity, scheduling, and contract terms are not disclosed.

Compliance and Facilities

ProMed Pharma has more than 15,000 square feet of ISO Class 7 manufacturing and clinical build facilities, and has established a 20,000-square-foot Pharma Development Facility in Maple Grove. In terms of its quality system, the materials state that it complies with 21 CFR 210/211 and 820, is ISO13485 certified, is an FDA-registered company, and has more than 15 years of inspection history.

Pros and Cons

Its strengths lie in its high level of vertical specialization, with the ability to connect formulation, process development, analytics, clinical supply, and commercial manufacturing, supported by dedicated project managers coordinating across multiple teams. Its drawbacks are that the publicly available information is more focused on capability presentation, with limited details on pricing, case studies, capacity, and service boundaries. At the same time, it is not a software platform and does not offer the cloud deployment, permissions, APIs, or third-party integrations commonly associated with SaaS products.

Who It’s For and Access from China

It is better suited for pharmaceutical, biotechnology, and medical device companies, especially teams developing controlled-release implants, long-acting injectables, ophthalmic products, or intrauterine/subcutaneous implant products. The materials do not provide information on access from China, so this remains unknown.